Özet:

Acute myeloid leukemia (AML) is a clinically morphologically and genetically heterogeneous disease with variable responses to therapy. The majority of the patients eventually relapse and succumb to the disease. Therapeutic modalities of induction chemotherapy, consolidation, and bone marrow transplantation are intended to achieve complete remission. Induction therapy with cytarabine and anthracycline remains thestandard of care in AML. Consolidation treatment is necessary to prevent recurrence, which may reach 90% without this treatment. Options for consolidation therapy are conventional chemotherapy and bone marrow transplantation. Bone marrow transplantation represents the only realistic chance of long-term remission in patients with a high cytogenetic risk. The risk of recurrence of AML is determined mainly by the patient’s age and genetic factors. In younger patients, complete remission (CR) rates of ≥80% may be achieved, with 5-year overall survival (OS) of 40%. InDr. Hasan Sadikin Hospital Bandung during the period of 2013-2018, 12 cases of LMA underwent chemotherapy. This case study discusses a young patient with AML who has successfully reached complete remission using induction and consolidation chemotherapy without bone marrow transplantation.   

Anahtar Kelimeler: